QIWI reports 2Q14 results on Aug 7 (BMO). We look for almost 30% yoy
growth of revenue to ~RUB2 bn, ~54% EBITDA margin and $0.43 in EPS
(JPMe is ~5% above both sell-side and buy-side consensus). We see a high
risk of Qiwi raising its FY14 guidance post the results. Qiwi trades on
16.5x 2015E P/E vs. payments peer average of ~19x and ~24.5x for
V/MA. We reiterate our high conviction on the name with an OW rating
and see the announcement of potential M&A within money remittance
space as a short-term catalyst that could move our year estimates up.
Well said. 40 coming by Friday
I am so tired of hearing about the comparison of these two stocks. Grow up people. ISIS is going to explode. It has the best PIPE in biotech right now. Try and bash all you want. There is no stopping this high flyer now. Look for 37 Monday. Called a short squeeze. Wouldn't be surprised if we go over 40 next week.
also add to long-term appeal of the stock.
With the shares down about 7% based upon the financing, we believe an attractive opportunity exists initiate or add to positions in NVAX. There is mounting evidence of the “respiratory vaccine” as a major biotech commercial success, driven by sound science, a growing clinical database and a focused management team. NVAX is a BUY under 6 with a TARGET PRICE of 13.
Special Update Novavax (NVAX) –Follow-On Offering Creates Buying Opportunity; Proceeds Will Accelerate “Respiratory Vaccine” Timeline
Last night, NVAX announced a $100 million secondary offering of common stock. The underwriters are JPMorgan and Citibank, two global banks that currently do not cover the stock from a research standpoint. After speaking with management, the use of proceeds is to fund a standalone elderly trial that will accelerate the path to approval for the disruptive/novel combination flu/RSV vaccine.
On May 12th, the company announced longer-term follow up from last year’s elderly RSV study that provided vaccination protection over 4-6 months (http://finance.yahoo.com/news/one-rsv-f-protein-vaccine-130000136.html). As a result, the company now has a potential “seasonal” vaccine strategy. Prior to this, there was no standalone elderly path to approval. The new path provides the earliest license/commercialization potential for the “respiratory vaccine” – the combination of the flu/RSV program into a single vaccine that, in our view, will be highly differentiated and lead the company into the combined $5 billion market for flu and RSV vaccines. As a reminder, the NVAX F Protein RSV vaccine just completed its fourth clinical trial since last year, and the company is about to meet with the FDA to begin the first RSV trial in pregnant women.
With the biotech sector beginning to rebound from the sharp pullback, NVAX included, a dilutive offering seemed a bit surprising – as the company has ~$130 million in cash and government funding (and no debt). However, in light of the new data from May 12 – there is a strong likelihood of accelerated development of the crown jewels. The company will, after the deal, be able to fund all major markets – maternal immunization, pediatrics and now the elderly. In addition, incorporating major distribution, market marking and investment research from two of the larger, well-respected banks, in our view, will als
Didn't they say no raise was on the HORIZON? Or did someone make that up? I can only think that great news will come tomorrow and a stock double at least. Someone knows something, that's why the stock volume has been going crazy. You do the math.....
This stock can't get going and don't tell me it's made a move since the last drop. It looks like it wants to trace downward back to $3.50. I hope not but getting tired of this B.S. with all this great news. Where are the buyers if this stock is so hot?
Medical Technology Stock Letter | The Mega-Mergers – A Look From Biotech E
NVAX Delivers Positive Phase II RSV Vaccine Data and MERS Vaccine Candidate is Published in Vaccine: NVAX announced positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase II trial in 720 women of childbearing age. The randomized, blinded, placebo-controlled Phase II study was designed to evaluate the immunogenicity and safety of Multiple formulations of NVAX' RSV-F protein nanoparticle vaccine adjuvanted with aluminum phosphate. The primary outcome of the trial was safety and immune response, measured by levels of serum IgG antibody specific for the F protein. Participants received either one or two intramuscular injections featuring two different dose levels of vaccine antigen with a range of doses of aluminum phosphate adjuvant. These top-line data over the 91-day period following first immunization were highly successful for safety and efficacy and support NVAX' maternal immunization strategy. With four positive studies in more than 1,100 safety subjects, the current trial represents a major step forward and another de-risking event. Highlights of the interim results include the following:
•The RSV-F vaccine candidate was well tolerated, with no vaccine-related serious adverse events, at all doses and formulations. The safety profile was consistent with data from prior Phase I and II studies.
•Significant increases in RSV-F antibody levels were observed across all doses and formulations, consistent with prior studies. Peak RSV-F antibody levels were observed in the group that received a single dose of vaccine containing 120 μg of antigen with one-third of the aluminum phosphate dose used in prior studies.
•Clear increases in RSV neutralizing antibodies were also shown across all doses and formulations, and were strongest in women entering the study with the lowest baseline levels, in confirmation of prior studies.
What a JOKE, can't even win when we get what we want. Please explain someone? Should be up a couple bucks minimum on this news.